← Back to Search
In Vitro Anti-mesothelioma Activity Of Cisplatin–gemcitabine Combinations: Evidence For Sequence-dependent Effects
I. Zanellato, Carla Doriana Boidi, G. Lingua, P. Betta, S. Orecchia, E. Monti, D. Osella
Published 2010 · Biology, Medicine
Download PDFAnalyze on Scholarcy
PurposeThe present study addresses the optimization of gemcitabine–cisplatin protocols currently adopted in the clinical management of malignant pleural mesothelioma (MPM), using cell lines derived from different histological subtypes of MPM as an in vitro model.MethodsMPM cell lines were exposed either to single drugs or to their combinations, using a fixed dose ratio. Possible mechanisms for synergistic interactions were investigated by cell cycle analysis, western blot analysis of p53 phosphorylation status, and neutral comet assay to detect double strand breaks.ResultsFour-hour pre-treatment with gemcitabine followed by 68-h exposure to cisplatin was found to exert synergistic activity in both epithelioid and sarcomatoid MPM subtypes, inducing a strong S-phase arrest that correlated with accumulation of double-strand breaks (DSBs).ConclusionThe antiproliferative effects of the gemcitabine/cisplatin combination in mesothelioma cells can be maximized by pre-treatment with gemcitabine, suggesting that this drug increases cisplatin-induced DSBs by inhibiting DNA adduct repair.
This paper references
The p53 family and programmed cell death
E. Pietsch (2008)
Synergistic interaction between cisplatin and gemcitabine in vitro.
A. Bergman (1996)
Survival of pleural malignant mesothelioma in Italy: A population‐based study
F. Montanaro (2009)
Interstrand crosslink repair: can XPF-ERCC1 be let off the hook?
D. T. Bergstralh (2008)
Pathology and genetics of tumours of the lung , pleura, thymus and heart
W. D. Travis (2004)
Excitatory amino acid inhibitors for traumatic brain injury
A. Gauden (2012)
Mechanisms of Dealing with DNA Damage-Induced Replication Problems
Magda Budzowska (2008)
Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis.
T. Berghmans (2002)
DNA Damage-Induced Phosphorylation of p53 Alleviates Inhibition by MDM2
S. Shieh (1997)
Double-strand breaks: signaling pathways and repair mechanisms.
T. Karagiannis (2004)
Influence of cis-diamminedichloroplatinum(II) on DNA synthesis and cell cycle progression in excision repair proficient and deficient Chinese hamster ovary cells.
C. M. Sorenson (1988)
Scheduling of gemcitabine and cisplatin in Lewis lung tumour bearing mice.
C. J. van Moorsel (1999)
Cancer testis antigens expression in mesothelioma: role of DNA methylation and bioimmunotherapeutic implications
L. Sigalotti (2002)
Expression of ERCC1 antisense RNA abrogates gemicitabine-mediated cytotoxic synergism with cisplatin in human colon tumor cells defective in mismatch repair but proficient in nucleotide excision repair.
L. Yang (2000)
Divided dose of cisplatin combined with gemcitabine in malignant mesothelioma.
G. Utkan (2006)
EVects of gemcitabine on cis-platinum-DNA adduct formation and repair in a panel of gemcitabine and cisplatin-sensitive or -resistant human ovarian cancer cell lines
GJ Peters (2006)
Systemic Treatments for Mesothelioma: Standard and Novel
H. Kindler (2008)
ects of gemcitabine on cis - platinum - DNA adduct formation and repair in a panel of gemcitabine and cisplatin - sensitive or - resistant human ovarian cancer cell lines
GJ Peters (2006)
Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines
C. V. Moorsel (1999)
Synergistic inhibition of pancreatic adenocarcinoma cell growth by trichostatin A and gemcitabine.
M. Donadelli (2007)
Effects of gemcitabine on cis-platinum-DNA adduct formation and repair in a panel of gemcitabine and cisplatin-sensitive or -resistant human ovarian cancer cell lines.
G. Peters (2006)
Application of immunohistochemistry to the diagnosis of malignant mesothelioma.
A. Marchevsky (2008)
AN EXPERIMENTAL DESIGN IN COMBINATION CHEMOTHERAPY
N. Mantel (1958)
World Health Organization Classification of Tumours
C. Fletcher (2002)
Participation of p53 protein in the cellular response to DNA damage.
M. Kastan (1991)
Status of the p53 tumor suppressor gene in human squamous carcinoma cell lines.
M. Reiss (1992)
Clinical relevance of the homologous recombination machinery in cancer therapy
K. Miyagawa (2008)
Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2',2'-difluorodeoxycytidine.
V. Heinemann (1990)
Aberrant E-cadherin and gamma-catenin expression in malignant mesothelioma and its diagnostic and biological relevance.
S. Orecchia (2004)
Application of an ATP-bioluminescence assay in human tumor chemosensitivity testing.
B. U. Sevin (1988)
Schedule-dependent antagonism of gemcitabine and cisplatin in human anaplastic thyroid cancer cell lines.
W. Voigt (2000)
Cellular pharmacology of gemcitabine.
E. Mini (2006)
Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: a phase II study of the Southwest Oncology Group (SWOG 9810).
S. Kalmadi (2008)
Selective cell kill of the combination of gemcitabine and cisplatin in multilayered postconfluent tumor cell cultures.
J. Padrón (1999)
DNA repair mechanisms involved in gemcitabine cytotoxicity and in the interaction between gemcitabine and cisplatin.
M. Crul (2003)
Valproate, in Combination with Pemetrexed and Cisplatin, Provides Additional Efficacy to the Treatment of Malignant Mesothelioma
F. Vandermeers (2009)
Histone deacetylase inhibitors enhance the chemosensitivity of tumor cells with cross‐resistance to a wide range of DNA‐damaging drugs
Kei-ichi Ozaki (2008)
Synergistic effect of the anti‐HER‐2/neu antibody and cisplatin in immortalized and primary mesothelioma cell lines
S. Toma (2002)
Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.
T. Chou (1984)
Pemetrexed disodium in combination with cisplatin versus other cytotoxic agents or supportive care for the treatment of malignant pleural mesothelioma.
J. Green (2007)
Biochemical mechanisms of cisplatin cytotoxicity.
V. Cepeda (2007)
This paper is referenced by
Metallo-drugs in the treatment of malignant pleural mesothelioma
I. Zanellato (2012)
Validation and application of Drosophila melanogaster as an in vivo model for the detection of double strand breaks by neutral Comet assay.
A. Sharma (2011)
The cisplatin-based Pt(iv)-diclorofibrato multi-action anticancer prodrug exhibits excellent performances also under hypoxic conditions.
E. Gabano (2018)
Evaluation of Platinum–Ethacrynic Acid Conjugates in the Treatment of Mesothelioma
I. Zanellato (2011)
Preclinical studies identify novel targeted pharmacological strategies for treatment of human malignant pleural mesothelioma
R. Favoni (2012)
Host–guest inclusion systems of Pt(IV)-bis(benzoato) anticancer drug candidates and cyclodextrins
M. Ravera (2015)
In vitro screening of synergistic ascorbate-drug combinations for the treatment of malignant mesothelioma.
S. Martinotti (2011)
Investigating heterogeneity of growth and drug response in mesotheliomas
Roxanne Otadoy (2013)
Biological activity of a series of cisplatin-based aliphatic bis(carboxylato) Pt(IV) prodrugs: how long the organic chain should be?
I. Zanellato (2014)
How to obtain Pt(iv) complexes suitable for conjugation to nanovectors from the oxidation of [PtCl(terpyridine)].
E. Gabano (2017)
DNA Repair Polymorphisms and Treatment Outcomes of Patients with Malignant Mesothelioma Treated with Gemcitabine-Platinum Combination Chemotherapy
N. Erčulj (2012)
The hexacarbonyldicobalt derivative of aspirin acts as a CO-releasing NSAID on malignant mesothelioma cells.
I. Zanellato (2013)
A new platinum‐based prodrug candidate: Its anticancer effects in B50 neuroblastoma rat cells
B. Rangone (2018)
Antiproliferative activity of Pt(IV)-bis(carboxylato) conjugates on malignant pleural mesothelioma cells.
Manuela Alessio (2013)
Sequence‑dependent effect of gemcitabine and cisplatin on A549 non‑small‑cell lung cancer cells.
Y. Tang (2013)
Polyanionic Biopolymers for the Delivery of Pt(II) Cationic Antiproliferative Complexes
M. Ravera (2016)
Synthesis, characterization and antiproliferative activity on mesothelioma cell lines of bis(carboxylato)platinum(IV) complexes based on picoplatin.
M. Ravera (2012)